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and Haishan Zeng, PhD*
Introduction: Preneoplastic lesions of the bronchial tree have a
high probability of developing into malignant tumors. Currently, the
best method for localizing them for further treatment is a combined
white light bronchoscopy (WLB) and autofluorescence bronchos-
copy (AFB) (WLB  AFB). The average specificity from large
clinical trials for this combined detection method is approximately
60%, leading to many false positives. The object of this study is to
determine whether adding point laser Raman spectroscopy (LRS) to
a WLB  AFB has the potential to improve the specificity of
preneoplastic lesion detection and what the implication is to the
detection sensitivity.
Methods: An LRS system was developed to collect real-time, in
vivo lung spectra with a fiber optic catheter passed down the
instrument channel of a bronchoscope. WLB  AFB imaging
modalities were used to identify lesions from 26 subjects, from
which 129 Raman spectra were measured. Multivariate statistical
analyses were performed on the spectra with a leave-one-out
crossvalidation.
Results: Clear in vivo Raman spectra were obtained in 1 second.
The location of individual Raman peaks in the spectra correlated
well with the known positions of Raman peaks generated by lipids,
proteins, and water molecules. Preneoplastic lesions were detected
with a sensitivity of 96% and a specificity of 91%.
Conclusion: Adding point LRS analysis to WLB  AFB imaging
has the ability to detect preneoplastic lesions in real time with high
sensitivity and specificity. The use of LRS has great potential for
substantially reducing the number of false-positive biopsies associated
with WLBAFB with very little reduction in the detection sensitivity.
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(J Thorac Oncol. 2011;6: 1206–1214)
Preneoplastic lesions of the bronchial airways includingmoderate and severe dysplasia and carcinoma in situ have
a high probability of developing into malignancies.1,2 Local-
izing these preneoplastic lesions during a bronchoscopy so
that further treatment can be administered is key to increasing
the patient’s chances of survival.3 In the 1990s, the adjunct
use of autofluorescence bronchoscopy (AFB) with white light
bronchoscopy (WLB) was developed and has made signifi-
cant improvements to the localization of preneoplastic le-
sions.3–11 The relative sensitivity from several single and
multicenter clinical trials using AFB  WLB for detecting
preneoplasias was on average twofold larger (1.5–6.3) than
WLB alone. Nevertheless, the average specificity of these
trials was only 60%, which leads to many false-positive
biopsies.7–11 This suboptimal figure is partially dependent on
the experience of the bronchoscopist to select which, out of
the many, tissue sites identified with WLB  AFB to biopsy.
Nevertheless, the main reason for the high number of false
positives is the low specificity inherent with AFB, because
benign lesions (including inflammation) and preneoplastic
lesions present with similar autofluorescence characteristics.
Thus, there is still a great need for improved detection
methods.
The advent of digital videoendoscopes has resulted in
clearer images, and initial trials with them have produced
promising sensitivity and specificity values for detecting
preneoplasias when combined with AFB.12 Preliminary re-
sults also show an added discriminatory benefit for preneo-
plastic lesions by combining narrow band imaging with
AFB.13 Nevertheless, neither of these methods have been
tried in large scale, multicenter, clinical trials, and they still
require subjective decision making by the bronchoscopist on
which sites to biopsy. Presently, it is not clear what the best
way forward will be.14,15 Laser Raman spectroscopy (LRS) is
a technology that has not been explored to any great extent
for in vivo characterization of lung lesions despite it being
hailed as the optical modality with the most potential for
detecting early tissue diseases.16 LRS involves exposing the
tissue to low-power laser light and collecting the scattered
light for spectroscopic analyses.16 It is a powerful technology
because spectra are obtained nondestructively, and light scat-
tered from samples with different molecular compositions
can be easily differentiated. The uptake of Raman by the
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medical community has been slow though mainly due to the
lack of equipment in the past sensitive enough to measure the
weak Raman emission. Nowadays, equipment has advanced
to the point where using Raman to detect early cancers and
precancers in vivo is feasible.17 Although fast in vivo Raman
imaging is still not possible, and thus, it cannot be used by
itself to rapidly localize diseased tissue, point Raman spectra
would be helpful in reducing the number of false-positive
biopsies if WLB AFB are first used to rapidly identify sites
of concern.18 The advantage is that the highly specific Raman
spectrum would enable an instantaneous and objective mea-
sure of whether a lesion is preneoplastic, malignant, or
neither. This will increase the specificity compared with
WLB  AFB alone without a large sacrifice in detection
sensitivity and without overly prolonging procedure times.
In this study, we report on a pilot study conducted to
test whether adding an in vivo Raman spectroscopy measure-
ment to WLB  AFB imaging can improve the specificity of
detecting lesions with pathologies of moderate dysplasia or
worse (MOD) and at what cost to the detection sensitivity.
MATERIALS AND METHODS
Raman systems have been developed for in vivo mea-
surements on several organs other than the lung.19–24 Initially,
prospects looked good for adapting Raman for in vivo lung
measurements as malignancies were identified in ex vivo
tissue with a high sensitivity and specificity by ourselves25
and others.26 The preferred method of incorporating Raman
into the lung clinic was to use the instrument channel of
existing bronchoscopes. Nevertheless, a Raman catheter di-
ameter of 2 mm was needed to fit the bronchoscope
channel, which is much smaller than similar catheters de-
signed for other organs19–24 which would severely limit the
collection efficiency of the Raman emission. Furthermore,
frequent and uncontrollable lung movements make it difficult
to maintain the focus of the Raman catheter for more than a
few seconds.
We overcame the restrictions to obtaining good quality
in vivo Raman spectra of the lung27 by using components to
reduce fiber emission28 and promote a high signal-to-noise
ratio.20 Our LRS system shown in Figures 1A, B, enabled
real-time in vivo Raman measurements of the lung for the
first time and with a short data acquisition time of 1 second.
The traditional measurement range of 0 to 2000 cm1 was
abandoned because of the very strong lung tissue autofluo-
rescence found by ourselves27 and others29 results in poor
photon counting statistics for the simultaneously measured
weak Raman. Instead, the 1500 to 3400 cm1 range was
used, which still contains significant biomolecular informa-
tion but much less autofluorescence.30 The system was
mounted on a small cart and wheeled close to the subject for
the procedure (Figure 1C).
FIGURE 1. A, Schematic showing the Raman
system (not to scale), with magnified views of
the fiber tips. *The location of a 50 m diame-
ter fiber used to calibrate the spectrometer. B,
The distal end of the Raman catheter (1.8 mm
diameter). C, The complete Raman system
mounted on moveable cart.
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The BC Cancer Agency Research Ethics Board ap-
proved the clinical test of the LRS system for the lung
(certificate H06-00010). Subjects attending a bronchoscopy
procedure as part of their medical care were invited to take
part in the trial. The participants were current or former
smokers older than 40 years who had smoked 20 pack-
years enrolled as part of a National Cancer Institute spon-
sored lung cancer chemoprevention trial (P01 CA096964)
and patients suspected to have lung cancer who were sched-
uled for a diagnostic bronchoscopy at the British Columbia
Cancer Agency. Informed patient consent was obtained. The
procedure was for the bronchoscopist to identify lesions they
would normally biopsy using combined WLB and AFB
(Figures 2A, B). Raman spectra were obtained from these
sites (Figure 2C). Biopsies were taken of the same locations
and classified by a pathologist. Eight classifications were
used according to WHO criteria31: normal epithelium, hyper-
plasia (including goblet cell hyperplasia and basal/reserve
cell hyperplasia), metaplasia (including immature squamous
metaplasia and squamous metaplasia), mild dysplasia, mod-
erate dysplasia, severe dysplasia, carcinoma in situ, and
invasive squamous cell carcinoma (IC). The presence or
absence of inflammatory changes was also recorded. Alto-
gether 46 patients participated; of these, 26 were found to
have suspicious areas with WLB  AFB. One hundred
twenty-nine Raman spectra were obtained: 51 of these were
from sites with pathologies of MOD, the rest were from
sites with pathologies of mild dysplasia or better (MILD).
The raw Raman spectra have to be standardized
before they can be analyzed or compared with published
spectra.32 The procedure was to first subtract the ambient
background signal from the raw data of each spectrum and
then calibrate for the sensitivity of the system as a function of
wavelength. The standardized procedure then continued in
one of three different ways. In the first case (dataset A), each
spectrum was smoothed (with a three-point moving aver-
age33) to remove random noise and then normalized to reduce
the effect of intensity variations from different tissue sites
with the same pathology. The normalization was accom-
plished by summing the area under each curve and dividing
each variable in the smoothed spectrum by this sum. In the
second case (dataset B), each spectrum was also smoothed,
but in this case, the autofluorescence was subtracted by a
modified polynomial fitting routine34 before normalization.
The third method (dataset C) used a Savitzky-Golay35 six-
point quadratic polynomial on each spectrum to calculate a
smoothed second-order derivative spectrum. Summing the
squared derivative values of a spectrum and then dividing
each variable by this sum was used for normalization.
Datasets A, B, and C were analyzed separately using
statistical software (Statistica 6.0, StatSoft Inc., Tulsa, OK).
Multivariate statistics were used, which compare whole spec-
tra rather than single Raman peaks (univariate) as these have
been shown be more accurate.36 Principle components (PCs)
for all the spectra in each dataset were computed to reduce the
number of variables. Student’s t tests were used on PCs that
accounted for 0.1% or more of the variance to determine
those most significant at separating spectra into two pathol-
ogy groups: MOD and MILD. A linear discrimination
analysis (LDA) with leave-one-out crossvalidation was used
on the most significant PCs. To avoid over fitting the data, the
number of PCs used in the LDA was limited to one third17 of
the total number of cases of the smallest subgroup, i.e., 51
MOD spectra. The complete analyses of spectra from datasets
A, B and Cwere redone a second time as described above except
that all the spectra with IC pathology (24 in total) were dropped
from each dataset (27 in total). Spectra in each dataset remained
with MOD pathology classification, and thus, only nine PCs
were used in the LDA crossvalidation model.
Raman spectra of reference materials that are the main
contributors to emissions from human epithelia and connec-
tive tissues were obtained for comparison. These were DNA
purified from a human placenta, RNA from baker’s yeast,
phenylalanine, tyrosine, tryptophan, triolein (an abundant
lipid of the bronchial mucus37), collagen from human lung,
and human hemoglobin. Most reference samples were ob-
tained from Sigma-Aldrich Canada Ltd. with the following
reference numbers: DNA (D4642), RNA (R6750), phenylal-
anine (P2126), tyrosine (T3754), tryptophan (T0254), triolein
(T7140), and human lung collagen (CH783). The hemoglobin
was from the blood sample of a volunteer. The references
were used neat in their supplied state without further process-
FIGURE 2. Pictures showing images acquired by a multimode bronchoscopy system. A, White light image and (B) blue light
excited fluorescence image (Xillix, Onco-LIFE) of the same location as (A). For image (B), green is representative of normal tis-
sue, and dark red (center of image) is diseased tissue. C, Same lesion being excited simultaneously with blue light to generate
a fluorescence image and with 785 nm light from the Raman catheter, which can be seen in the top right corner of the im-
age.
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ing. Spectra were obtained using the same equipment as the
in vivo measurements by supporting the Raman catheter a
few millimeters above the sample. The data were prepro-
cessed in the same way as the in vivo data and then further
processed as for dataset B spectra.
RESULTS
There was a substantial autofluorescence contribution
to dataset A spectra, with relatively small Raman peaks
around 1600, 2150, and 2900 cm1 (Figure 3). The low
intensity broad peak centered at 2150 cm1 and the intense
emission rising above 3100 cm1 are assigned to water
molecule vibrations.38 Figure 4 shows in vivo spectra pro-
cessed as dataset B; the Raman peaks seen in data set A
spectra are now clearly visible. The broad peaks near 1663
cm1 were most likely due to a combination of  (C  O)
amide I vibrations27 and 2 water molecule bending mo-
tions.38,39 The broad peak around 2900 cm1 is assigned to a
combination of lipid (C-H) peaks (2833  2886 cm1) and
generic protein vibrations at 2938 cm1.
FIGURE 3. Average spectra for da-
taset A processed data from sites with
pathology MILD (upper green
curve) and MOD (middle red
curve). The two averages have been
shifted on the intensity scale for clar-
ity. The lower plot (blue curve) shows
the result of subtracting the average
MILD spectra from the average
MOD spectra (not on the same in-
tensity scale). The horizontal dashed
line is at zero intensity. MOD, le-
sions with pathology of moderate
dysplasia or worse; MILD, lesions
with pathology of mild dysplasia or
better.
FIGURE 4. Spectra of dataset B
processed data. The spectra are the
averages of the different pathology
classifications, which have been
shifted along intensity axis for clar-
ity. Two ranges (A and B) are shown
as this was only where clear Raman
peaks were observed. The spectra in
(A) were on average five times less
intense than those in (B).
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There were other small peaks or shoulders in the
spectra shown in Figure 4 at 1589, 1646, 1698, 1727, 2720,
2801, 2863, 2877, and 2921 cm1 that are in agreement with
the peaks of many amino acids, lipids, and proteins.39,40
Between 1750 and 2700 cm1 of the emission range (not
shown in Figure 4), there were a number of narrow peaks
with very low intensities, apart from the broad emission at
2150 cm1, that did not seem to vary for different lung sites.
This spectral region is not noted for any significant Raman
peaks, although there are reports of some weak Raman
emissions mainly due to carbon and nitrogen modes39 that
were in approximate agreement with some of the very low
intensity peaks observed. Nevertheless, our data were too
noisy in this region, probably due to residual optical fiber
emissions27 and small charge coupled device etaloning ef-
fects,41 to be useful.
Figure 5 shows the Raman spectra of some of the
reference samples measured. The spectra have features con-
sistent with those in the literature, see e.g., Movasaghi et al.39
and references therein.
Figure 6 shows the average Raman spectra of MOD
and MILD lesions. The two mean spectra show significant
differences (p  0.05) at 13 wave number locations (indi-
cated by vertical dashed lines in Figure 6). These locations
correspond to either peaks or shoulders in the spectra. An
approximate fit to each average spectrum was obtained with
a least squares weighted sum of all the references measured.
These fits showed relative increases in DNA, hemoglobin,
phenylalanine, and triolein for MOD lesions and a corre-
sponding drop in collagen.
The second-derivative spectra of dataset C, over the
ranges where significant differences (p  0.05) between
different pathology groups were apparent, are shown in
Figure 7.
The statistical analyses on spectra from datasets A, B
and C led to significantly different results. Spectra from
dataset A were the worst in predicting the pathology MOD
with 80% sensitivity and 72% specificity (Table 1). Remov-
ing the IC spectra from analyses resulted in a substantially
worse sensitivity with only a modest increase in specificity. If
spectra were only classified when the posterior probability
was 0.7 or 0.3, then 80% sensitivity and 77% specificity
were obtained at the cost of only being able to classify 99 of
129 spectra (77%).
Analyses of dataset B spectra showed an improvement
in pathology prediction compared with dataset A spectra with
80% sensitivity and 79% specificity. Removing the IC spectra
from analyses this time resulted in a substantially better
specificity (89%) with the sensitivity unchanged. When using
cutoff lines at 0.7 and 0.3, the sensitivity and specificity were
83% and 84%, respectively, and 80% of the 129 spectra were
classified.
The best result was obtained by analyzing spectra
processed with the second-order derivative (dataset C);
90% sensitivity and 91% specificity were obtained using
all the spectra. In this case, only three IC spectra were
misclassified (Figure 8). Dropping all the IC spectra from
analyses resulted in the sensitivity increasing to 96% with
the specificity unchanged at 91%, and when using the 0.7
and 0.3 cutoff lines, both sensitivity and specificity in-
creased with 88% of spectra classified. The receiver oper-
ator characteristics for all the three datasets are shown in
Figure 9. One can clearly see the superiority of second-
order derivative processed spectra (dataset C). The frac-
tional areas under each receiver operator characteristic
curve were 0.78, 0.85, and 0.92 for spectra analyzed in
datasets A, B, and C, respectively.
FIGURE 5. Spectra of the reference
samples (phenylalanine not shown).
These spectra were processed the
same way as dataset B in vivo data.
The spectra have been shifted along
intensity axis for clarity. Two ranges
(A and B) are shown as these were
only where clear Raman peaks were
observed.
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DISCUSSION
The maximum autofluorescence intensity was still sig-
nificant over the measurement range used in this study, but it
was an order of magnitude less than found over the traditional
(fingerprint) range.27 Furthermore, despite there being fewer
Raman peaks in the measurement range, there were statisti-
cally significant differences in the spectra for sites with
different pathologies. Although there did not seem to be any
consistent trend in the changes to individual peaks (Figure 4)
as the pathology of the tissue goes through the various
FIGURE 6. Average spectra of dataset B processed data from sites with pathology MILD (upper green curve) and MOD
(middle red curve). The two averages have been shifted on the intensity scale for clarity. The lower plot (blue curve) shows
the result of subtracting the average MILD spectra from the average MOD spectra (not on the same intensity scale). The
horizontal dashed line is at zero intensity. Two ranges (A and B) are shown as these were only where clear Raman peaks were
observed. The vertical dashed lines are the wave numbers where the two averages had the most significant difference as de-
termined by a t test statistic. Also shown (solid black curves) are the results of least square fit to the average spectra using a
weighted linear combination of all the reference spectra measured. MOD, lesions with pathology of moderate dysplasia or
worse; MILD, lesions with pathology of mild dysplasia or better.
FIGURE 7. Average spectra of data-
set C processed data from sites with
pathology MILD (upper green
curve) and MOD (middle red
curve). The two averages have been
shifted on the intensity scale for clar-
ity. The lower plot (blue curve) shows
the result of subtracting the average
MILD spectra from the average
MOD spectra (not on the same in-
tensity scale). The horizontal dashed
line is at zero intensity. Two ranges (A
and B) are shown as these were only
where clear Raman peaks were ob-
served. MOD, lesions with pathol-
ogy of moderate dysplasia or worse;
MILD, lesions with pathology of
mild dysplasia or better.
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changes from normal to IC. This observation probably relates
to the complex nonlinear biomolecular changes that occur
demonstrating the needed for multivariate statistical analyses
where the whole spectrum is used.
Although fitting the Raman spectra with a combination
of reference spectra showed the expected biomolecular
changes for diseased tissue,25 the fits were not precise prob-
ably due to an insufficient number of references used. Refit-
ting the spectra with an expanded set of reference spectra
would be required to determine with more confidence which
biomolecules have changed and by how much.
The statistical analyses of dataset A spectra were dis-
appointing but not entirely unexpected. The site selection
process was biased toward only selecting sites that were
identified by the AFB imaging system algorithm, but it is
known that this results in a less than optimal specificity. As it
is generally not difficult to identify IC using a combination of
WLB and AFB, dropping the IC spectra from the data
analyses may improve detection of early stage disease. In the
case of dataset A spectra, this reasoning proved false with
only 55% of spectra from MOD sites identified. The obvi-
ous explanation for this is that autofluorescence dominates
the spectra and that this autofluorescence is similar for all
sites measured except those with IC.
The use of cutoff lines in analyses was in recognition of
the fact that it was occasionally difficult to get good quality
spectra. Patient involuntary movements were suspected as one
cause of this problem, another was significant mucus or water on
the tissue surface. It will be difficult to totally eliminate this
problem, and thus, some real-time method of assessing the
quality of a spectrum will be needed if Raman proves to be
beneficial in a multicenter clinical trial. As the equipment is
designed to work in the clinic, in real time, one possibility is to
use cutoff lines to enable the bronchoscopist to immediately take
another spectrum if the previous spectrum did not meet a tough
statistical standard of being MOD or MILD. Any sites that
failed after several attempts could be biopsied. The cutoff lines
should not be made too strict; otherwise, this would defeat the
object of decreasing the number of false positives. As a test, 0.7
and 0.3 posterior probability cutoffs were chosen for this pilot
study, although for dataset A processed spectra, these only led to
a 5% increase in specificity and no change in sensitivity.
FIGURE 8. Posterior probability
plot of predicted pathology com-
pared with known pathology. Statis-
tical analyses were performed on
dataset C data (second-order deriva-
tive spectra) gathered into spectra
from MILD and MOD tissue sites
using a leave-one-out crossvalida-
tion. A total of 17 PCA components
were used in the LDA model. LDA,
linear discrimination analysis;
MOD, lesions with pathology of
moderate dysplasia or worse;
MILD, lesions with pathology of
mild dysplasia or better.
TABLE 1. Classification Results
Dataset Subdataset Sensitivity Specificity No. of Spectra Classified
A All data 80% 72% 51 MOD, 78 MILD
All data minus IC 55% 76% 27 MOD, 78 MILD
70, 30 80% 77% 35 MOD, 64 MILD
B All data 80% 79% 51 MOD, 78 MILD
All data minus IC 89% 79% 27 MOD, 78 MILD
70, 30 83% 84% 40 MOD, 63 MILD
C All data 90% 91% 51 MOD, 78 MILD
All data minus IC 96% 91% 27 MOD, 78 MILD
70, 30 93% 96% 45 MOD, 68 MILD
MOD, lesions with pathology of moderate dysplasia or worse; MILD, lesions with pathology of mild dysplasia or better.
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Analyses of dataset B spectra produced better results
than dataset A, although there were some spectra from IC
sites that were misclassified. The reason for this was most
likely sampling errors, as IC lesions may contain areas other
than the histologically malignant epithelium (i.e., desmopla-
tic stroma). Sampling of the adjacent reactive or inflamed
nonneoplastic tissue is another possibility for the misclassi-
fied samples. Removing the IC spectra from analyses did
increase the specificity by 9% with the sensitivity unchanged.
Posterior probability cutoff lines made modest improvements
to the sensitivity and specificity.
The second-order derivative spectra (dataset C) were
the best at separating MOD and MILD tissue with 90%
sensitivity and 91% specificity. Dropping the IC spectra sees
the sensitivity rise by 6% with no loss in specificity. Apart
from the IC spectra, the other misclassified sites were those
with moderate dysplasia, mild dysplasia, metaplasia, and
hyperplasia pathologies. Sampling errors may again explain
these misclassifications. Although an alternative explanation
for the misclassifications is that the Raman spectra contain
biomolecular information, with no obvious histological coun-
terpart,11,42 on whether a lesion will develop into late-stage
disease or not. More work is needed to test this theory.
It is not fully understood why processing data with a
second-order derivative leads to the improvement observed in
the sensitivity and specificity values. The major reason is
thought to be that inaccuracies in the polynomial fitting of the
substantial autofluorescence introduce an uncorrelated vari-
ance into dataset B. Other methods of removing the back-
ground fluorescence have been proposed such as shifted
subtracted Raman spectroscopy,26 but all have their advan-
tages and disadvantages as explained by Zhao et al.34 Their
method works well for noncomplex background fluorescence
and is fast for real-time clinical applications. Generating a
derivative spectrum is also a fast process that can be done in
the clinic in real time, and thus, this may be the optimal
choice with intensely fluorescing tissue.
In conclusion, it seems that point LRS can significantly
reduce the number of false-positive biopsies, whereas mar-
ginally reducing the sensitivity of WLB and AFB to the
detection of preneoplastic lung lesions. Although it may be
considered better to have a 40% false-positive rate than incur
any loss in detection sensitivity, the slight loss incurred with
the adjunct use of Raman may not be realized in practice. First,
bronchoscopists currently have to make partially subjective
decisions when using WLB  AFB about which lesions to
biopsy. The adjunct use of Raman would make the decision
process more objective, which may result in the identification of
additional preneoplastic lesions at sites initially rejected as bi-
opsy candidates. Second, as mentioned earlier, Raman may be
able to identify biomolecular changes in both histologically
preneoplastic and nonpreneoplastic lesions that are markers for
development into late-stage disease. If this proves to be correct,
then the relative sensitivity of LRS WLB  AFB for detect-
ing premalignant lesions will actually increase compared with
WLB  AFB alone. More work is needed to follow-up on this
pilot study and to test the conclusions we have arrived at, but the
evidence so far points to Raman spectroscopy as having great
potential for improving the early detection of preneoplastic
lesions.
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